Continuing Medical Education (CME) Grants
Alnylam Pharmaceuticals' CME Grants fund independent, evidence-based education for healthcare professionals on ATTR amyloidosis, AHP, and PH1.
Browse similar grants
Funder: Alnylam Pharmaceuticals
Due Dates: Rolling (Applications accepted anytime; submit at least 45 days before activity start)
Funding Amounts: No fixed maximum; award size determined case-by-case, may be less than requested.
Summary: Supports independent, evidence-based educational activities for healthcare professionals focused on ATTR amyloidosis, AHP, and PH1.
Key Information: Only organizations (not individuals) with valid tax status are eligible; applications reviewed monthly.
Description
Alnylam Pharmaceuticals offers Continuing Medical Education (CME) Grants to support independent, high-quality educational activities aimed at healthcare professionals. These grants target educational gaps and encourage innovative programs in three core disease areas: transthyretin-mediated amyloidosis (ATTR amyloidosis), acute hepatic porphyria (AHP), and primary hyperoxaluria type 1 (PH1). Funded activities must be evidence-based, unbiased, and compliant with all applicable legal, regulatory, and accreditation standards. The program emphasizes transparency, scientific rigor, and the independence of educational content and faculty.
